The company's investigational DCV Dual Regimen (daclatasvir and asunaprevir) is a combination therapy for genotype 1b chronic hepatitis C infection (HCV). The special designation means that the ...
daclatasvir + asunaprevir × 24 weeks Grp B: daclatasvir + asunaprevir + PEG-IFNα2a + RBV × 24 weeks SVR12 2: Sofosbuvir + RBV (12 weeks) + PEG-IFN (4 weeks) 3: Sofosbuvir + RBV (12 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback